EP cancer control move promising for medtech
This article was originally published in Clinica
Executive Summary
The EU market for diagnostic tests and imaging procedures for diagnosing cancer, as well as for radiotherapy equipment, would "explode" if the European Parliament was able to push through all of its proposals for tackling cancer that are contained in a Resolution adopted by MEPs during a debate on April 10. One third of cancers in the EU could be cured if detected early and treated appropriately. Another third are preventable, the Parliament stated in its motion for the resolution that was adopted.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.